Neurochemical Research
April 1, 2023
Jared VanderZwaag, Torin Halvorson, Kira Dolhan et al.
25 citations
There is much excitement surrounding recent research of promising, mechanistically novel psychotherapeutics - psychedelic, anesthetic, and dissociative agents - as they have demonstrated surprising efficacy in treating central nervous system (CNS) disorders, such as mood disorders and addiction. However, the mechanisms by which these drugs provide such profound psychological benefits are still...
Neuropsychiatric Disease and Treatment
March 31, 2023
Xu Chen, Xuan Hou, Daisy Bai et al.
Purpose: This Phase 3, multicenter study (NCT03434041) was conducted in primarily Chinese patients with treatment-resistant depression (TRD) to support the registration of esketamine nasal spray in China. Patients and methods: This randomized, double-blind, active-controlled study was conducted in China and the United States (US) in patients with TRD (single or recurrent episode). Eligible...
Pakistan Armed Forces Medical Journal
March 30, 2023
Asif Azeem Bajwa, Sohail Ali, Sikandar Ali Khan et al.
1 citation
Objective: To evaluate and compare the efficacy of Electroconvulsive therapy (ECT) and Ketamine infusions in hospitalized patients suffering from major depressive disorder (MDD). Study Design: Comparative cross-sectional study. Place and duration of study: Armed Forces Institute of Mental Health, Rawalpindi Pakistan, from Feb to Apr 2021. Methodology: Forty in-patients diagnosed as having MDD...
Bipolar Disorders
March 28, 2023
Balwinder Singh
Ketamine is a novel drug used for treatment- resistant depression. The initial randomized controlled trials (RCTs) established intravenous (IV) ketamine's rapid antidepressant effects for refrac-tory major depression, leading to its widespread use. However, the data for ketamine's efficacy in treatment- resistant bipolar depression (TRBD) remain minimal. There are 3 single infusion RCTs ( n =...
The International Journal of Neuropsychopharmacology
March 26, 2023
T. Su, Cheng-Ta Li, Wei-Chen Lin et al.
48 citations
Abstract Background The benefits of low-dose ketamine for patients with treatment-resistant depression (TRD) and prominent suicidal ideation require further investigation. The effects of treatment refractoriness, the duration of the current depressive episode, and the number of prior antidepressant failures on ketamine efficacy also require clarification. Methods We recruited 84 outpatients...
Psychiatry Research
March 15, 2023
Ibrahim Turkoz, J. Craig Nelson, Samuel T. Wilkinson et al.
19 citations
This exploratory post hoc analysis of two pooled 4-week, phase 3, double-blind, placebo- and active-controlled studies that compared esketamine nasal spray plus a newly initiated oral antidepressant (ESK+AD; n = 310) with a newly initiated oral AD plus placebo nasal spray (AD+PBO; n = 208) in patients with treatment-resistant depression (TRD) examined baseline patient demographic and...
Neuropsychiatric Disease and Treatment
March 14, 2023
Cheng-Chuan Chen, Na Zhou, Na Hu et al.
Purpose: Suicide is a major public health concern with currently no validated and efficacious treatments approved. Preliminary evidence suggests that intravenous ketamine has rapid and sustained antidepressant effects, making it a candidate with therapeutic potential for depressed patients at risk for suicide. We conducted a meta-analysis to evaluate the efficacy of ketamine and esketamine in...
Trends in Psychiatry and Psychotherapy
March 7, 2023
Ana Teresa Caliman-Fontes, Gustavo C. Leal, Fernanda S. Correia-Melo et al.
Objectives: Evidence suggests that ketamine's influence on brain-derived neurotrophic factor (BDNF) might be involved in its mechanism of rapid antidepressant action. We aimed to evaluate the differential impact of ketamine and esketamine on serum BDNF levels and its association with response patterns in treatment-resistant depression (TRD). Methods: Participants (n = 53) are from a randomized,...
Biomedicines
March 7, 2023
Hans O. Kalkman
16 citations
Depression is a major public health concern. Unfortunately, the present antidepressants often are insufficiently effective, whilst the discovery of more effective antidepressants has been extremely sluggish. The objective of this review was to combine the literature on depression with the pharmacology of antidepressant compounds, in order to formulate a conceivable pathophysiological process,...
Psychiatry Research
March 5, 2023
Kevork Danayan, Noah Chisamore, Nelson B Rodrigues et al.
36 citations
Borderline personality disorder (BPD) has high rates of comorbidity with mood disorders, including treatment-resistant depression (TRD). Comorbidity of BPD with depression is associated with poorer response to antidepressants. Intravenous ketamine is a novel treatment for TRD that has not been specifically evaluated in patients with comorbid BPD. In this retrospective analysis of data collected...